# Pharmacogenomics

Source: https://onco.cc/terms/pharmacogenomics-term/  
OnCo record `pharmacogenomics-term` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pharmacogenomics studies how a person's genes, and a tumour's genes, change the way drugs work or cause harm.

## Summary

Pharmacogenomics, abbreviated PGx, is the study of the role of the genome in drug response, combining pharmacology and genomics to ask how a patient's genetic makeup affects their reaction to drugs (Wikipedia). In oncology it covers both inherited variants that govern toxicity (DPYD and fluoropyrimidines, TPMT and thiopurines) and the tumour's somatic alterations that predict sensitivity, the basis of cell-line drug-response prediction.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: pharmacogenomics; pharmacogenomic; pharmacogenetics; PGx
- Tags: cansim-terms

## Notes

- Listed in the CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme; CanSim page path /terms/pharmacogenomics.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pharmacogenomics
- Wikipedia: https://en.wikipedia.org/wiki/Pharmacogenomics

## Connected records

- terms: [Actionable genomic biomarkers](https://onco.cc/terms/cancer-drivers-vs-actionable/), [Cancer AI vocabulary (CanSim terms map)](https://onco.cc/terms/cancer-ai-vocabulary/), [Drug response and drug sensitivity (IC50, AUC)](https://onco.cc/terms/drug-response-sensitivity/)
- technologies: [Pharmacogenomic testing before chemotherapy](https://onco.cc/technologies/oncology-pharmacogenomics/)

---
JSON: https://onco.cc/api/v1/entities/pharmacogenomics-term.json